Alithea Genomics Closes CHF 6.9 M Seed Round, Using Proceeds to Unlock Industrial-Scale RNA-seq for Primary Drug Screening and Toxicology
Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of its seed financing round with an additional CHF 3 million ($3.9 million), led by Genku Ventures and joined by Novalis Biotech and Zürcher Kantonalbank as well as several private investors. This additional funding brings the total seed round to CHF 6.9 million ($8.9 million). The proceeds will be used primarily to accelerate commercialization of its new 1536‑well MERCURIUSTM DRUG-seq kits unlocking greater potential of using cell transcriptomics in primary drug screening and exploratory toxicology. These applications, previously out of reach due to cost and throughput constraints, can now be addressed by scaling 3′RNA‑seq library preparation to 1,536 samples. Alithea will also invest the proceeds in accelerating new technology development and building proprietary transcriptomic data assets to fuel the industry's AI/ML initiatives.
Alithea Genomics Launches Full-Length DRUG-Seq to Unlock Full Power of Transcriptomics for Drug Discovery
Alithea Genomics, a leader in the field of large-scale RNA sequencing and transcriptomics, announced today the launch of MERCURIUS™ Full-Length DRUG-seq library preparation technology, which combines, for the first time, massive sample multiplexing, an extraction-free workflow and full transcript coverage in a unique RNA-seq workflow. The technology is compatible with both 96- and 384-well plate formats and up-to 384 full-length RNA-seq library preps can be performed in a single tube without RNA isolation.
Alithea Genomics Closes CHF 2.8 Million in Seed Financing Extension Led by Novalis Biotech
Alithea Genomics, an emerging leader in the field of large-scale RNA sequencing and transcriptomics, announced today the closing of a CHF 2.8 million ($3.2 million) extension to its seed financing. The round was led by the Novalis Biotech Acceleration fund and included new investor TechU Ventures alongside existing investors. The proceeds will be used to continue commercialization and expand manufacturing capacity of its unique RNA sequencing products, advance the development of new technologies and establish a subsidiary in the United States.
Alithea Genomics Raises CHF 1 Million in Seed Financing Round Led by Novalis Biotech
Alithea Genomics, a fast-growing, emerging leader in the field of RNA sequencing and transcriptomics analysis, announced today the closing of a CHF 1 million seed financing round led by the Novalis Biotech Acceleration fund, with participation of Swiss-based private investors.
